Estimates suggest that a single treatment of the drug, Radicava, costs $1,000, leading to a price tag of $150,000 to $180,000 per year.
In clinical trials, Radicava slowed the progression of ALS by 33 percent, giving patients an additional year to 18 months of functional life.
The FDA approved Radicava to be used on any patient; however, most insurance companies are refusing to cover patients who had the disease for more than two years, according to Scott Vota, DO, director of the ALS Clinic at VCU Medical Center.
“The majority of our [ALS] patients are getting denied,” Jason Wong, MD, assistant professor of neurology at VCU Medical Center’s ALS Clinic, told the Richmond Times Dispatch.
Even though claims are being denied, the team at the clinic is fighting to expand insurance coverage of the new treatment.
More articles on supply chain:
US Bioservices to pay $13.4M to resolve kickback suit
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
